Associated Papers
Understanding Hypertriglyceridemia: Integrating Genetic Insights.
Alves M et al.
Genes, 2024
Genetics and regulation of HDL metabolism.
Kardassis D et al.
Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids, 2022
Ethnic differences in ApoC-III concentration and the risk of cardiovascular disease: No evidence for the cardioprotective role of rare/loss of function APOC3 variants in non-Europeans.
Rout M et al.
American Heart Journal Plus : Cardiology Research and Practice, 2022
APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease.
Xu QY et al.
Biomed Research International, 2020
Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease.
Dai W et al.
Lipids in Health and Disease, 2019
Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR et al.
Current Atherosclerosis Reports, 2019
A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
Khetarpal SA et al.
Nature Medicine, 2017
What can we learn about lipoprotein metabolism and coronary heart disease from studying rare variants?
Jeff JM et al.
Current Opinion in Lipidology, 2016
Association of APOC3 Loss-of-Function Mutations With Plasma Lipids and Subclinical Atherosclerosis: The Multi-Ethnic BioImage Study.
Natarajan P et al.
Journal of the American College of Cardiology, 2015
Loss-of-function mutations in APOC3, triglycerides, and coronary disease.
Crosby J et al.
The New England Journal of Medicine, 2014
APOC3 may not be a predictor of risk of ischemic vascular disease in the Chinese population.
Tang L et al.
F1000research, 2014
Select a paper to view details